Amgen's ovarian cancer drug trials disappoint

November 5, 2014 2:45 AM

16 0

Ovarian cancer drug fails to improve overall survival rate in clinical trial. Amgen announces results of late-stage trial of drug trebananib(Photo : NIH)

In a late-stage trial of an ovarian cancer drug known as trebananib, it failed to result in significantly improved patient survival, the drug's maker Amgen, Inc., has reported.

Read more

To category page